RxDoctor Payments DataLook up a doctor →

William Bundrick, MD

Urology · Bossier City, LANPI 1326087354

Payments from drug & device makers

$7,925in general payments, 2019–2025

Across 358 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$643
  • Pfizer$623
  • Sun Pharmaceutical Industries Inc.$582
  • Sumitomo Pharma America, Inc.$529
  • Endo Pharmaceuticals Inc.$435
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,67697%
  • Education$2493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,925 in reported general payments places this provider in the 75th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$474,742
Medicare patients
1,163
Services billed
7,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron26$17,645
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst349$16,603
GemtesaVibegron22$16,496
Fosfomycin Tromethamine20$15,867
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav584$14,467
ErtapenemErtapenem Sodium47$13,077
Trimethoprim184$12,777
Tamsulosin Hcl876$12,656
Cefdinir204$8,264
Testosterone22$6,379
Methenamine Hippurate93$5,014
Doxycycline Hyclate167$4,405
Ciprofloxacin Hcl227$2,864
Cefaclor13$2,641
Cefepime Hcl13$2,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$643$17,64526 claims
Sumitomo Pharma America, Inc.Gemtesa$529$16,49622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 199 urology providers in Louisiana.

Other urology in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →